•
Sep 30, 2023
Enliven Therapeutics Q3 2023 Earnings Report
Reported third quarter financial results and provided a business update.
Key Takeaways
Enliven Therapeutics reported its Q3 2023 financial results, highlighting progress in Phase 1 trials for ELVN-001 and ELVN-002, with initial proof of concept data expected in 2024. The company closed the quarter with $263.5 million in cash, cash equivalents, and marketable securities, expected to provide cash runway into early 2026.
Patient enrollment continues to progress for ELVN-001 and ELVN-002.
Enliven expects to report initial proof of concept data in 2024 for ELVN-001 and ELVN-002.
The Company continues to advance its early-stage pipeline.
As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $263.5 million.